Teladoc Inc (TDOC) Shares Sold by Macquarie Group Ltd.
Macquarie Group Ltd. decreased its position in shares of Teladoc Inc (NYSE:TDOC) by 35.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 99,014 shares of the health services provider’s stock after selling 55,135 shares during the period. Macquarie Group Ltd.’s holdings in Teladoc were worth $5,748,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. We Are One Seven LLC increased its position in Teladoc by 241.1% during the first quarter. We Are One Seven LLC now owns 2,845 shares of the health services provider’s stock worth $115,000 after buying an additional 2,011 shares during the period. Garner Asset Management Corp acquired a new position in Teladoc during the second quarter worth approximately $200,000. Pier 88 Investment Partners LLC acquired a new position in Teladoc during the second quarter worth approximately $201,000. Aperio Group LLC acquired a new position in Teladoc during the second quarter worth approximately $201,000. Finally, Biondo Investment Advisors LLC acquired a new position in Teladoc during the second quarter worth approximately $205,000.
Teladoc stock opened at $80.75 on Wednesday. The company has a current ratio of 3.14, a quick ratio of 3.14 and a debt-to-equity ratio of 0.58. Teladoc Inc has a 1-year low of $27.30 and a 1-year high of $82.40. The company has a market capitalization of $5.43 billion, a P/E ratio of -48.94 and a beta of 0.57.
A number of research firms have recently issued reports on TDOC. Canaccord Genuity boosted their target price on Teladoc from $47.00 to $63.00 and gave the company a “buy” rating in a report on Tuesday, June 5th. Craig Hallum raised Teladoc from a “hold” rating to a “buy” rating in a report on Tuesday, June 5th. Robert W. Baird boosted their target price on Teladoc from $50.00 to $65.00 and gave the company a “neutral” rating in a report on Wednesday, July 25th. Chardan Capital boosted their target price on Teladoc from $73.00 to $86.00 and gave the company a “buy” rating in a report on Friday, August 3rd. Finally, MED boosted their target price on Teladoc to $56.00 and gave the company a “hold” rating in a report on Thursday, June 7th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $67.80.
In related news, insider Stephany Verstraete sold 18,000 shares of Teladoc stock in a transaction that occurred on Thursday, September 20th. The stock was sold at an average price of $74.79, for a total value of $1,346,220.00. Following the sale, the insider now directly owns 13,925 shares in the company, valued at $1,041,450.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, President Peter A. Mcclennen sold 91,072 shares of Teladoc stock in a transaction that occurred on Monday, July 16th. The shares were sold at an average price of $65.84, for a total value of $5,996,180.48. Following the completion of the sale, the president now owns 61,660 shares in the company, valued at $4,059,694.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 286,781 shares of company stock worth $19,429,607. Company insiders own 3.95% of the company’s stock.
Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
See Also: Growth Stocks
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Inc (NYSE:TDOC).
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.